Tenet Healthcare Corporation (NYSE:THC) Stock Has Consensus Price Target of $277.25

Key Points

• Analysts broadly favor Tenet Healthcare: Eighteen of 21 covering firms rate the stock a buy, producing a “Moderate Buy” consensus and an average 12-month price target of $277.25.
• Tenet reported quarterly EPS of $6.12, exceeding the $4.26 consensus estimate, while revenue reached $6.04 billion and rose 6.8% year over year.
• The stock opened at $260.17, near its $283.05 52-week high. Institutional investors own 95.44% of shares, while company insiders sold 131,199 shares worth approximately $35.1 million during the last quarter.

Shares of Tenet Healthcare Corporation (NYSE:THC - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-one research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and eighteen have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $277.25.

Several research analysts have recently issued reports on THC shares. TD Cowen increased their price target on Tenet Healthcare from $233.00 to $263.00 and gave the stock a "buy" rating in a research note on Monday, July 27th. Robert W. Baird lifted their target price on Tenet Healthcare from $210.00 to $280.00 and gave the stock a "neutral" rating in a report on Tuesday, July 28th. Weiss Ratings raised shares of Tenet Healthcare from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, August 20th. Leerink Partners reiterated an "outperform" rating and issued a $309.00 price objective on shares of Tenet Healthcare in a research note on Friday, September 18th. Finally, Guggenheim increased their price target on shares of Tenet Healthcare from $242.00 to $283.00 and gave the stock a "buy" rating in a research note on Tuesday, July 28th.

Insider Buying and Selling

In other Tenet Healthcare news, EVP Lisa Foo sold 24,000 shares of the firm's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $266.32, for a total transaction of $6,391,680.00. Following the completion of the transaction, the executive vice president owned 8,053 shares in the company, valued at $2,144,674.96. This trade represents a 74.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nadja West sold 1,152 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $258.80, for a total value of $298,137.60. Following the transaction, the director owned 23,653 shares of the company's stock, valued at $6,121,396.40. This represents a 4.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 131,199 shares of company stock valued at $35,065,587 in the last quarter. Insiders own 0.97% of the company's stock.

Institutional Investors Weigh In On Tenet Healthcare

A number of hedge funds have recently modified their holdings of the business. Trust Co. of Vermont acquired a new position in shares of Tenet Healthcare in the second quarter valued at approximately $37,000. OP Asset Management Ltd acquired a new position in shares of Tenet Healthcare during the 1st quarter worth about $49,000. Compass Financial Management LLC acquired a new stake in Tenet Healthcare in the 2nd quarter valued at about $57,000. William B. Walkup & Associates Inc. grew its holdings in Tenet Healthcare by 88.7% during the fourth quarter. William B. Walkup & Associates Inc. now owns 302 shares of the company's stock worth $60,000 after purchasing an additional 142 shares during the period. Finally, Capital Advisors Ltd. LLC increased its position in Tenet Healthcare by 11,933.3% during the first quarter. Capital Advisors Ltd. LLC now owns 361 shares of the company's stock worth $68,000 after buying an additional 358 shares during the last quarter. Institutional investors and hedge funds own 95.44% of the company's stock.

Tenet Healthcare Price Performance

NYSE THC opened at $260.17 on Tuesday. The company has a 50-day moving average price of $262.76 and a two-hundred day moving average price of $215.04. Tenet Healthcare has a 52 week low of $157.58 and a 52 week high of $283.05. The stock has a market cap of $20.95 billion, a price-to-earnings ratio of 10.03, a price-to-earnings-growth ratio of 0.99 and a beta of 1.20. The company has a current ratio of 1.41, a quick ratio of 1.35 and a debt-to-equity ratio of 2.00.

Tenet Healthcare (NYSE:THC - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.The business had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. During the same period in the previous year, the firm posted $4.02 earnings per share. The business's revenue was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Analysts forecast that Tenet Healthcare will post 21.04 EPS for the current year.

About Tenet Healthcare

Tenet Healthcare Corporation is a Dallas-based healthcare services company that operates hospitals, outpatient facilities and other healthcare businesses across the United States. Its operations include acute care hospitals, specialty hospitals, ambulatory surgery centers and related outpatient services.

Through its United Surgical Partners International subsidiary, Tenet is one of the major operators and developers of ambulatory surgery centers in the United States. These facilities provide same-day surgical procedures and other outpatient care across a range of medical specialties.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.